Home / Press
Press
Press and media
Are you writing a story, looking for an interview partner or would you like to visit our laboratory? We are happy to help.
Press releases
Official announcements
EVANIUM’s OPTISOLV® Berberine Recognized as Most Innovative Nutraceutical Ingredient at Vitafoods Europe Startup Challenge 2026
OPTISOLV® Berberine won the award for Most Innovative Nutraceutical Ingredient at the Vitafoods Europe Startup Challenge 2026 in Barcelona.
EVANIUM Raises €2.2 Million Seed Round to Solve One of the Most Expensive Inefficiencies in the Nutraceutical Industry
FoodLabs and Feast Ventures back OPTISOLV® Technology. The €2.2 million seed round accelerates EVANIUM’s ingredient platform, clinical validation and market expansion.
In the media
EVANIUM in the press
VITAFOODS EUROPE
NUTRAINGREDIENTS
VITAFOODS INSIGHTS
NUTRACEUTICAL BUSINESS REVIEW
STARTUP RESEARCHER
Boilerplate
About EVANIUM and OPTISOLV®
Feel free to use these texts in your article.
About EVANIUM
EVANIUM is a Germany-based life-science company developing innovative ingredients based on its IP-protected drug delivery technology OPTISOLV®. The company improves key properties such as solubility, stability and bioavailability of ingredients for applications in nutraceuticals, functional foods, cosmetics and pharmaceuticals. Founded in 2019 and headquartered at the BioPark Regensburg, EVANIUM works with industry partners to unlock the full potential of ingredients.
About OPTISOLV®
Built around a dual-coating system, OPTISOLV® combines an inner cyclodextrin-based core with an outer phospholipid shell, stabilising natural actives in a crystal-free, highly dispersible state. This structure improves solubility, release and permeability, using only natural excipients. For OPTISOLV® Curcumin, water solubility is more than 1,000× higher and release during digestion up to 170× better than with native curcumin.
Key facts
Company
Evanium Healthcare GmbH
Founded
2019, Regensburg, Germany
Headquarters
Am Biopark 13, 93053 Regensburg
Founders
Felix Rolka (CEO), David Ofner (CTO), Carlo Werkmann
Funding
EUR 2.5 M in total, incl. EUR 2.2 M seed round 2026
Recognition
Most Innovative Nutraceutical Ingredient, Vitafoods Europe 2026
Writing a story?
Interviews, lab visits, images or background information: our press team gets back to you quickly.